Associate
Emma Ng focuses on complex patent litigation and client counseling in areas related to biotechnical and pharmaceutical innovations. She represents clients before U.S. district courts and the U.S. Court of Appeals for the Federal Circuit, with a particular emphasis on litigating Abbreviated New Drug Application (ANDA) cases.
Emma has extensive experience litigating high-stakes pharmaceutical cases, including matters involving billion-dollar and top-selling blockbuster drugs. Her work has provided her with deep insight into successful litigation strategies for innovator pharmaceutical companies.
Emma’s litigation practice spans federal district courts, appeals before the U.S. Court of Appeals for the Federal Circuit, and confidential arbitration proceedings. She is actively involved in all phases of litigation, from pre-litigation counseling and case strategy development to fact and expert discovery as well as claim construction. Her primary focus is on ANDA litigation and disputes involving medical device innovations and trade secrets. Emma’s work has contributed to favorable outcomes for clients, including successful settlements.
Emma is committed to pro bono service and has been recognized multiple times on the Capital Pro Bono High Honor Roll for her representation of asylum seekers, including securing a grant of asylum for a client. She has also successfully represented veterans before the U.S. Court of Appeals for Veterans Claims and the Naval Discharge Review Board and has volunteered with the Election Protection Hotline.
During law school, Emma gained international legal experience as a Milt Stewart Fellow in China, where she assisted with client counseling, global trademark portfolio protection, and trademark enforcement.
Member, Planning Committee, Finnegan's Together We Soar Summit, 2024-2025.
Co-author. Lasting Impact: Why You Should Care About Court of Customs and Patent Appeal Cases, AIPLA Quarterly Journal, 51, 39, 2023.
Audio editor, Indiana University IP Theory Law Journal, 2020-2021.
Participant, AIPLA Giles Sutherland Rich Moot Court Competition, 2021.
Student volunteer, Indiana University Intellectual Property Law Clinic, 2020.
Dean's Writing Fellow, 2019-2020.
Participant, Sherman Minton Moot Court, Oral Advocacy Honors, 2018.
Incyte Corporation et al. v. Sun Pharmaceutical Industries Limited et al.
Successfully represented Incyte in patent litigation, including preliminary injunction proceedings related to Sun Pharmaceuticals’ deuterated Janus kinase (JAK) inhibitor, LEQSELVI™. Case settled favorably for our client.
2:24-cv-06944, D.N.J., Judge Padin
AbbVie Inc., et al. v. Aurobindo Pharma U.S.A., Inc. et al.
Finnegan is representing AbbVie, Allergan, and Merck in ongoing ANDA litigation involving Ubrelvy®, indicated for the acute treatment of migraine with or without aura in adults.
3:24-cv-04603, D.N.J., Judges Quraishi, Day
3:24-cv-04662, D.N.J., Judges Quraishi, Day
3:24-cv-04852, D.N.J., Judges Quraishi, Day
Articles
Unpacking the PTAB’s Patent Age Denial Doctrine Data Unpacking the PTAB’s Patent Age Denial Doctrine Data
August 29, 2025
Intellectual Asset Management (IAM)Articles
Trending at the PTAB: IPR Memo and Its Fed. Circ. Backdrop Trending at the PTAB: IPR Memo and Its Fed. Circ. Backdrop
August 22, 2025
Law360Federal Circuit IP Blog
Don’t Sleep on This: Federal Circuit Reverses Permanent Injunction Barring Clinical Trials and New Indications for NDA Don’t Sleep on This: Federal Circuit Reverses Permanent Injunction Barring Clinical Trials and New Indications for NDA
May 20, 2025
Federal Circuit IP Blog
Federal Circuit Affirms Principle of Party Presentation Allows the Parties, Not the Court, to Chart the Course of a Litigation Federal Circuit Affirms Principle of Party Presentation Allows the Parties, Not the Court, to Chart the Course of a Litigation
October 9, 2024
At the PTAB Blog
Board’s Failure to Meet Statutory Deadline to Issue Final Written Decision Does Not Result in Loss of Board’s Jurisdiction Board’s Failure to Meet Statutory Deadline to Issue Final Written Decision Does Not Result in Loss of Board’s Jurisdiction
July 16, 2024
Federal Circuit IP Blog
PTAB’s Implicit Claim Construction in Obviousness Analysis Constitutes Claim Construction, Even When Its Decision States It Did Not Construe Claims PTAB’s Implicit Claim Construction in Obviousness Analysis Constitutes Claim Construction, Even When Its Decision States It Did Not Construe Claims
March 21, 2024
Award/Ranking
61 Finnegan Attorneys Recognized on the 2025 Capital Pro Bono Honor Roll 61 Finnegan Attorneys Recognized on the 2025 Capital Pro Bono Honor Roll
May 7, 2026
Award/Ranking
Finnegan Associates Honored with Young Lawyer of the Year Award Finnegan Associates Honored with Young Lawyer of the Year Award
December 7, 2025
Award/Ranking
56 Finnegan Attorneys Recognized on the 2024 Capital Pro Bono Honor Roll 56 Finnegan Attorneys Recognized on the 2024 Capital Pro Bono Honor Roll
April 24, 2025
DC BarDue to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.